Activation of PPARγ in Bladder Cancer Via Introduction of the Long Arm of Human Chromosome 9

Overview

Journal Oncol Lett

Specialty Oncology

Date 2022 Feb 14

PMID 35154423

Authors

Ryutaro Shimizu

Takahito Ohira

Takuki Yagyu

Tetsuya Yumioka

Noriya Yamaguchi

Hideto Iwamoto

Shuichi Morizane

Katsuya Hikita

Masashi Honda

Atsushi Takenaka

Hiroyuki Kugoh

Affiliations

Soon will be listed here.

Abstract

Bladder cancer is divided into two molecular subtypes, luminal and basal, which form papillary and nodular tumors, respectively, and are identifiable by gene expression profiling. Although loss of heterozygosity (LOH) of the long arm of human chromosome 9 (9q) has been observed in the early development of both types of bladder cancer, the functional significance of LOH remains to be clarified. The present study introduced human chromosome 9q into basal bladder cancer cell line, SCaBER, using microcell-mediated chromosome transfer to investigate the effect of LOH of 9q on molecular bladder cancer subtypes. These cells demonstrated decreased proliferation and migration capacity compared with parental and control cells. Conversely, transfer of human chromosome 4 did not change the cell phenotype. Expression level of peroxisome proliferator-activated receptor (PPAR)γ, a marker of luminal type, increased 3.0-4.4 fold in SCaBER cells altered with 9q compared with parental SCaBER cells. Furthermore, the expression levels of tumor suppressor PTEN, which regulates PPARγ, also increased in 9q-altered cells. These results suggested that human chromosome 9q may carry regulatory genes for PPARγ that are involved in the progression of neoplastic transformation of bladder cancer.

References

Grossman R, Heath A, Ferretti V, Varmus H, Lowy D, Kibbe W . Toward a Shared Vision for Cancer Genomic Data. N Engl J Med. 2016; 375(12):1109-12. PMC: 6309165. DOI: 10.1056/NEJMp1607591. View

Sonenberg N, Hinnebusch A . New modes of translational control in development, behavior, and disease. Mol Cell. 2007; 28(5):721-9. DOI: 10.1016/j.molcel.2007.11.018. View

Liu J, Zhang Y, Yu C, Zhang P, Gu S, Wang G . Bergenin inhibits bladder cancer progression via activating the PPARγ/PTEN/Akt signal pathway. Drug Dev Res. 2020; 82(2):278-286. DOI: 10.1002/ddr.21751. View

Cheng S, Qian K, Wang Y, Wang G, Liu X, Xiao Y . PPARγ inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells. J Cell Mol Med. 2019; 23(5):3724-3736. PMC: 6484405. DOI: 10.1111/jcmm.14280. View

Lindgren D, Sjodahl G, Lauss M, Staaf J, Chebil G, Lovgren K . Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS One. 2012; 7(6):e38863. PMC: 3369837. DOI: 10.1371/journal.pone.0038863. View

Zhou Y, Liang H, Liao Z, Wang Y, Hu X, Chen X . miR-203 enhances let-7 biogenesis by targeting LIN28B to suppress tumor growth in lung cancer. Sci Rep. 2017; 7:42680. PMC: 5316988. DOI: 10.1038/srep42680. View

Platt F, Hurst C, Taylor C, Gregory W, Harnden P, Knowles M . Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res. 2009; 15(19):6008-17. DOI: 10.1158/1078-0432.CCR-09-0898. View

Rampias T, Vgenopoulou P, Avgeris M, Polyzos A, Stravodimos K, Valavanis C . A new tumor suppressor role for the Notch pathway in bladder cancer. Nat Med. 2014; 20(10):1199-205. DOI: 10.1038/nm.3678. View

Chin L, Hahn W, Getz G, Meyerson M . Making sense of cancer genomic data. Genes Dev. 2011; 25(6):534-55. PMC: 3059829. DOI: 10.1101/gad.2017311. View

10.

Fadl-Elmula I . Chromosomal changes in uroepithelial carcinomas. Cell Chromosome. 2005; 4:1. PMC: 1199610. DOI: 10.1186/1475-9268-4-1. View

11.

Zhang Z, Xu H, Ji J, Shi X, Lyu J, Zhu Y . Heterogeneity of PTEN and PPAR-γ in cancer and their prognostic application to bladder cancer. Exp Ther Med. 2019; 18(4):3177-3183. PMC: 6755423. DOI: 10.3892/etm.2019.7879. View

12.

Bartoletti R, Cai T, Nesi G, Girardi L, Baroni G, Dal Canto M . Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer. J Surg Res. 2007; 143(2):422-7. DOI: 10.1016/j.jss.2007.01.012. View

13.

Wang G, Cao R, Wang Y, Qian G, Dan H, Jiang W . Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARγ signalling pathway. Sci Rep. 2016; 6:35783. PMC: 5078845. DOI: 10.1038/srep35783. View

14.

Kugoh H, Ohira T, Oshimura M . Studies of Tumor Suppressor Genes via Chromosome Engineering. Cancers (Basel). 2016; 8(1). PMC: 4728451. DOI: 10.3390/cancers8010004. View

15.

Czerniak B, Dinney C, McConkey D . Origins of Bladder Cancer. Annu Rev Pathol. 2016; 11:149-74. DOI: 10.1146/annurev-pathol-012513-104703. View

16.

Hau A, Nakasaki M, Nakashima K, Krish G, Hansel D . Differential mTOR pathway profiles in bladder cancer cell line subtypes to predict sensitivity to mTOR inhibition. Urol Oncol. 2017; 35(10):593-599. DOI: 10.1016/j.urolonc.2017.03.025. View

17.

Kugoh H, Mitsuya K, Meguro M, Shigenami K, Schulz T, Oshimura M . Mouse A9 cells containing single human chromosomes for analysis of genomic imprinting. DNA Res. 1999; 6(3):165-72. DOI: 10.1093/dnares/6.3.165. View

18.

Osei-Amponsa V, Buckwalter J, Shuman L, Zheng Z, Yamashita H, Walter V . Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer. Oncogene. 2019; 39(6):1302-1317. DOI: 10.1038/s41388-019-1063-4. View

19.

Mylona E, Giannopoulou I, Diamantopoulou K, Bakarakos P, Nomikos A, Zervas A . Peroxisome proliferator-activated receptor gamma expression in urothelial carcinomas of the bladder: association with differentiation, proliferation and clinical outcome. Eur J Surg Oncol. 2008; 35(2):197-201. DOI: 10.1016/j.ejso.2008.04.003. View

20.

Williamson M, Elder P, Shaw M, Devlin J, Knowles M . p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet. 1995; 4(9):1569-77. DOI: 10.1093/hmg/4.9.1569. View